Occurrence of demyelinating diseases after anti-TNFα treatment of inflammatory bowel disease: A Danish Crohn Colitis Database study

Journal of Crohn's and Colitis

Volumn 2, Issue 4, 2008, Pages 304-309

  Andersen, Nynne Nyboe ^a   Caspersen, Sarah ^a   Jess, Tine ^b   Munkholm, Pia ^a  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b The Capital Region   (Denmark)

Author keywords

Anti TNF ; Demyelinating disease; Inflammatory bowel disease; treatment

Indexed keywords

ADALIMUMAB; AZATHIOPRINE; CORTICOSTEROID; INFLIXIMAB; MESALAZINE; METHOTREXATE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ANKYLOSING SPONDYLITIS; ARTICLE; CROHN DISEASE; DEMYELINATING DISEASE; ELECTROMYOGRAM; ENTERITIS; HUMAN; LUMBAR PUNCTURE; MORBIDITY; MULTIPLE SCLEROSIS; MUSCLE BIOPSY; MUSCLE WEAKNESS; NUCLEAR MAGNETIC RESONANCE IMAGING; PREVALENCE; PRIORITY JOURNAL; SYSTEMATIC REVIEW;

EID: 56449093378     PISSN: 18739946     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.crohns.2008.04.001     Document Type: Article

References (28)

1. Targan S.R., Hanauer S.B., Van Deventer S.J., et al. A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med 337 (1997) 1029-1035
2. Hyams J., Crandall W., Kugathasan S., et al. Induction and maintenance infliximab therapy for the treatment of moderate-to-severe Crohn's disease in children. Gastroenterology 132 (2007) 863-873
3. Lawson M.M., Thomas A.G., and Akobeng A.K. Tumour necrosis factor alpha blocking agents for induction of remission in ulcerative colitis. Cochrane Database Syst Rev 3 (2006) CD005112
4. Thomas Jr. C.W., Weinshenker B.G., and Sandborn W.J. Demyelination during anti-tumor necrosis factor alpha therapy with infliximab for Crohn's disease. Inflamm Bowel Dis 10 (2004) 28-31
5. Mejico L.J. Infliximab-associated retrobulbar optic neuritis. Arch Ophthalmol 122 (2004) 793-794
6. Foroozan R., Buono L.M., Sergott R.C., et al. Retrobulbar optic neuritis associated with infliximab. Arch Ophthalmol 120 (2002) 985-987
7. Dubcenco E., Ottaway C.A., Chen D.L., et al. Neurological symptoms suggestive of demyelination in Crohn's disease after infliximab therapy. Eur J Gastroenterol Hepatol 18 (2006) 565-566
8. Freeman H.J., and Flak B. Demyelination-like syndrome in Crohn's disease after infliximab therapy. Can J Gastroenterol 19 (2005) 313-316
9. Ljung T., Karlen P., Schmidt D., et al. Infliximab in inflammatory bowel disease: clinical outcome in a population based cohort from Stockholm County. Gut 53 (2004) 849-853
10. Strong B.Y., Erny B.C., Herzenberg H., et al. Retrobulbar optic neuritis associated with infliximab in a patient with Crohn disease. Ann Intern Med 140 (2004) W34
11. www.fda.gov.
12. Greenlee J.E. Progressive multifocal leucoencephalopathy in the era of natalizumab: a review and discussion of the implications. Int MS J 13 (2006) 100-107
13. Yousry T.A., Major E.O., Ryschkewitsch C., et al. Evaluation of patients treated with natalizumab for progressive multifocal leukoencephalopathy. N Engl J Med 354 (2006) 924-933
14. Fauci A.S., Braunwald E., Isselbacher K.J., et al. Harrisons Principles of Internal Medicine. 14th ed (1998), McGraw-hill
15. S Caspersen, L Riis, M Elkjaer et al. Infliximab treatment in inflammatory bowel disease in Denmark 1999-2005: clinical outcome and follow-up on malignancy and mortality. 2007. In Submission.
16. Koch-Henriksen N. The Danish Multiple Sclerosis Registry: a 50-year follow-up. Mult Scler 5 (1999) 293-296
17. Kimura K., Hunter S.F., Thollander M.S., et al. Concurrence of inflammatory bowel disease and multiple sclerosis. Mayo Clin Proc 75 (2000) 802-806
18. Bernstein C.N., Wajda A., and Blanchard J.F. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 129 (2005) 827-836
19. Rang E.H., Brooke B.N., and Hermon-Taylor J. Association of ulcerative colitis with multiple sclerosis. Lancet 2 (1982) 555
20. Gupta G., Gelfand J.M., and Lewis J.D. Increased risk for demyelinating diseases in patients with inflammatory bowel disease. Gastroenterology 129 (2005) 819-826
21. Becker K.G., Simon R.M., Bailey-Wilson J.E., et al. Clustering of non-major histocompatibility complex susceptibility candidate loci in human autoimmune diseases. Proc Natl Acad Sci U S A 95 (1998) 9979-9984
22. Loftus Jr. E.V. Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology 126 (2004) 1504-1517
23. Pugliatti M., Sotgiu S., and Rosati G. The worldwide prevalence of multiple sclerosis. Clin Neurol Neurosurg 104 (2002) 182-191
24. van Oosten B.W., Barkhof F., Truyen L., et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 47 (1996) 1531-1534
25. Robinson W.H., Genovese M.C., and Moreland L.W. Demyelinating and neurologic events reported in association with tumor necrosis factor alpha antagonism: by what mechanisms could tumor necrosis factor alpha antagonists improve rheumatoid arthritis but exacerbate multiple sclerosis?. Arthritis Rheum 44 (2001) 1977-1983
26. Shin I.S., Baer A.N., Kwon H.J., et al. Guillain-Barre and Miller Fisher syndromes occurring with tumor necrosis factor alpha antagonist therapy. Arthritis Rheum 54 (2006) 1429-1434
27. Bellesi M., Logullo F., Di B.P., et al. CNS demyelination during anti-tumor necrosis factor alpha therapy. J Neurol 253 (2006) 668-669
28. Mohan N., Edwards E.T., Cupps T.R., et al. Demyelination occurring during anti-tumor necrosis factor alpha therapy for inflammatory arthritides. Arthritis Rheum 44 (2001) 2862-2869